- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, HEOR, Real-world evidence, BRCA Biomarker, Real-world: OSCA - Olaparib Standard of CAre Study (clinicaltrials.gov) - Feb 2, 2015 P=N/A, N=2000, Active, not recruiting, Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- |||||||||| Vigil (gemogenovatucel-T) / Gradalis
Enrollment closed, Enrollment change, Trial primary completion date, Tumor cell: Salvage Ovarian FANG (clinicaltrials.gov) - Feb 2, 2015 P2, N=1, Active, not recruiting, Trial primary completion date: Sep 2014 --> Sep 2016 Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Sep 2014 --> Jul 2015
- |||||||||| Trial primary completion date: 3DRCT: Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? (clinicaltrials.gov) - Jan 28, 2015
P1, N=42, Recruiting, Not yet recruiting --> Recruiting | N=43 --> 25 | Initiation date: Jun 2014 --> Jan 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- |||||||||| Norditropin (somatropin) / Novo Nordisk
Trial completion, Enrollment change: Microflare Protocol in Poor Responders (clinicaltrials.gov) - Jan 28, 2015 P4, N=145, Completed, Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Completed | N=198 --> 145
- |||||||||| veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, BRCA Biomarker, PARP Biomarker: Phase II ABT-888 With Cyclophosphamide (clinicaltrials.gov) - Jan 26, 2015 P2, N=29, Active, not recruiting, Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Dec 2014
- |||||||||| Cycloset (bromocriptine) / Bausch Health
Enrollment closed, Trial primary completion date: Vaginal Bromocriptine for Treatment of Adenomyosis (clinicaltrials.gov) - Jan 22, 2015 P1, N=33, Active, not recruiting, Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Mar 2017
- |||||||||| cabergoline / Generic mfg.
Enrollment change, Trial primary completion date: Cabergoline and Coasting to Prevent OHSS (clinicaltrials.gov) - Jan 20, 2015 P3, N=300, Recruiting, N=757 --> 460 | Active, not recruiting --> Terminated N=200 --> 300 | Trial primary completion date: Jun 2014 --> Mar 2015
- |||||||||| Phase classification: Ultrasound and Endometrial Hyperplasia (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=36, Terminated, N=200 --> 300 | Trial primary completion date: Jun 2014 --> Mar 2015 Phase classification: P1/2 --> P=N/A
|